Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin

  title={Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin},
  author={G. G. Neznamov and E. S. Teleshova},
  journal={Neuroscience and Behavioral Physiology},
cognitive disorders arises from their significant occurrence in the population [7, 8, 39–41], which is steadily increasing as populations age, with increases in trauma and ecological problems in most of the developed countries of the world. The most frequent cognitive impairments are those resulting from brain damage of vascular, traumatic, and intoxication origin and those forming as a result of neurodegenerative diseases [7, 10, 11, 21, 25–28]. “Mild” cognitive disorders are those involving… 
Piracetam and Piracetam-Like Drugs
Assessing the clinical outcomes as well as the scientific literature relating to the pharmacology, pharmacokinetics/pharmacodynamics, mechanism of action, dosing, toxicology and adverse effects of marketed and investigational drugs indicate notable improvements in clinical outcomes with some of these agents.
An Open Clinical Trial of Cortexin in Cerebral Ischemia
Treatment decreased or completely eliminated focal neurological symptomatology and produced positive changes in measures of cognitive impairments, these changes being accompanied by normalization of patients’ emotional status and decreases in the level of depression.
Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.
The review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 19 categories according to their mechanism(s) of action.
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Investigating the neuroprotective action of noopept on cellular model of AD, Aβ25–35-induced toxicity in PC12 cells and revealed the underlying mechanisms provide evidence that novel cognitive enhancer noopePT protects PC12 cell against deleterious actions of Aβ through inhibiting the oxidative damage and calcium overload as well as suppressing the mitochondrial apoptotic pathway.
Finding the optimal dosage for nootropic agent Noopept: An analysis of available literature
Noopept is a novel nootropic agent with various potential uses: as a neuroprotective agent, as a memory enhancer in older people with mild cognitive impairment, and as a way to significantly increase
Piracetam shows anti-depressant activity in experimental models of depression over a wide dose range and in a dose-dependent manner.
Piracetam and Piracetam-Like Drugs From Basic Science to Novel Clinical Applications to CNS Disorders
A major focus of the literature search was on articles demonstrating evidencebased clinical investigations during the past 10 years for the following therapeutic categories of CNS disorders: (i) cognition/memory; (ii) epilepsy and seizure; (iii) neurodegenerative diseases; (iv) stroke/ischaemia; and (v) stress and anxiety.
Five Unapproved Drugs Found in Cognitive Enhancement Supplements.
Over-the-counter cognitive enhancement supplements may contain multiple unapproved drugs, and consumers could be exposed to up to four-fold greater than pharmaceutical dosages and as many as 4 un approved drugs when using individual products.


Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia.
The precursor state and major subtypes of dementia are considered, the term given to patients with cognitive impairment that is detectable by clinical criteria but does not produce impairment in daily functioning.
Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action
It is postulate that if in Alzheimer’s disease overactivation of NMDA receptors occurs indeed, memantine would be expected to improve both symptoms (cognition) and slow down disease progression because it takes over the physiological function of magnesium.
Pharmacotherapy of Alzheimer Disease
  • D. Seow, S. Gauthier
  • Medicine, Psychology
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2007
The significant advances in the symptomatic pharmacotherapy of AD may be followed by disease-modification treatments, primarily with drugs reducing amyloid synthesis or aggregation.
Classification criteria for mild cognitive impairment
MCI criteria perform poorly when applied to a representative population sample, and the authors propose modifications to current diagnostic criteria to increase their capacity to detect incipient dementia.
Screening for organic mental syndromes in the medically ill.
A brief mental status questionnaire adapted specifically to diagnose diffuse organic diffuse organic mental syndromes on busy medical words is developed and tested for reliability and validity and the role of cognitive dificulty in medical patients is discussed.
Mild cognitive impairment: clinical characterization and outcome.
Patients who meet the criteria for MCI can be differentiated from healthy control subjects and those with very mild AD, and appear to constitute a clinical entity that can be characterized for treatment interventions.
Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease
Tests assessing new learning, delayed recall and attention/executive function seem to provide valuable information for screening and diagnosis of MCI and early AD if interpreted properly.
Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study
This three step procedure (self report of memory complaints, test of global cognitive functioning, and then domain specific cognitive tests) has a positive predictivity of 85-100% for Alzheimer's disease and dementia at three years However, only 18% of people in the preclinical phase can be identified using this procedure.
Quantitative cerebral anatomy of the aging human brain
Many elderly subjects did not exhibit cortical atrophy or lateral ventricular enlargement, however, indicating that such changes are not inevitable consequences of advancing age, and these data should provide a useful clinical context within which to interpret changes in regional brain size associated with “abnormal” aging.